Использование b 2 -адреномиметика длительного действия формотерола при лечении бронхиальной астмы
- Авторы: Емельянов А.В1
-
Учреждения:
- Санкт-Петербургская медицинская академия последипломного образования
- Выпуск: Том 9, № 3 (2007)
- Страницы: 47-51
- Раздел: Статьи
- URL: https://journal-vniispk.ru/2075-1753/article/view/92319
- ID: 92319
Цитировать
Полный текст
Аннотация
Среди лекарственных препаратов для лечения бронхиальной астмы (БА) различают средства для купирования симптомов (relievers) и для контроля (controllers) за течением заболевания [15]. Ингаляционный b2-адреномиметик длительного действия формотерол относится к препаратам как первой, так и второй группы.
Ключевые слова
Полный текст
Открыть статью на сайте журналаСписок литературы
- Anderson G.P, Linden A, Rabe K.F. Why are long - acting beta - adreno - ceptor agonists long acting? Eur Respir J 1994; 7 (3): 569–78.
- Aziz I, Wilson A.M, Lipworth B.J. Effect of once - daily formoterol and budesonide given alone and in combination on surrogate inflammatory markers in asthmatic adults. Chest 2000; 118 (4): 1049–58.
- Barnes P. Beta - adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995; 152 (3): 838–60.
- Barnes P. Effect of beta - agonists on inflammatory cells. J Allergy Clin Immunol 1999; 104 (2), pt 2: 10–7.
- Barnes P.J. Scientific rationale for inhaled combination therapy with long - acting b2-agonists and corticosteroids. Eur Respir J 2002; 19: 182–91.
- Bartow R.A, Brogden R.N. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998; 55 (2): 303–22.
- Bench G, Lapidus R, Levine B.E et al. A randomized, 12 week, double - blind, placebo - controlled study comparing formoterol dry powder inhaler with albuterol metered – dose inhaler. Ann Allergy Asthma Immunol 2001; 86 (1): 19–27.
- Bouros D, Bachlitzanakis N, Kottakis J et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur Respir J 1999; 14 (3): 627–32.
- Cazzola M, Imperatore F, Salzillo A et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrythmias and hypoxemia. Chest 1998; 114: 411–5.
- Cazzola M, Matera M.G, Donner C.F. Inhaled b2-adrenoreceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005; 65 (12): 1595–610.
- Centanni S, Carlucci P, Santus P et al. Non - pulmonary effects induced by addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma. Respiration 2000; 67 (1): 60–4.
- Ferrari M, Balestreri F, Baratieri S et al. Evidence of the rapid protective effect of formoterol dry - powder inhalation against exercise - induced bronchospasm in athletes with asthma. Respiration 2000; 67 (5): 510–3.
- Fit Gerald J.M, Chapman K.R, Della Cioppa G et al. Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/ODI Study Group. J Allergy Clin Immunol 1999; 103 (3), pt 1: 427–43.
- Ganderton D, Lewis D, Davies R et al. Modulite®: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96 (Suppl. D): S3–8.
- Global Initiative for Asthma. NHLB/WHO Workshop Report. - National Heart Lung Blood Institute, Publication number 95-3659, 2006-Chapter 3//www.ginasthma.org.
- Guhan A.R, Cooper S, Oborne J et al. Systemic effects of formoterol and salmeterol: a dose - response comparison in healthy subjects. Thorax 2000; 55 (8): 650–6.
- Hall I.P. Beta-2 adrenergic receptor dysfunction and polymorphism in asthma. UpToDate. Rose, BD (Ed),Waltham, MA, 2006.
- Handley D.A, Anderson A.J, Koester J, Snider M.E. New mellenium bronchodilators for asthma: single isomer beta agonists. Curr Opin Pulm Med 2000; 6 (1): 43–9.
- Ind P.W, Villasante C, Shiner R.J et al. Safety of formoterol by Turbuhaled as reliver medication compared with terbutaline in moderate asthma. Eur Respir J 2002; 20 (4): 859–66.
- Israel E, Drazen J.M, Liggett S.B et al. The effect of polymorphisms of the beta (2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162 (1): 75–80.
- Johnson M. The b - adrenoceptor. Am J Respir Crit Care Med 1998; 158 (5), pt. 3: 146–53.
- Juniper E, Svensson K, O’Burne P.M et al. Asthma quality of life during 1 year of treatment with budesonide with and without formoterol. Eur Respir J 1999; 14 (5): 1038–43.
- Kaik G, Kattakis I, Anagnostopoulou O et al. Sequential flexible therapy with formoterol (Foradil) plus budesonide (Miflonide) versus a fixed combination of salmeterol and fluticasone (Seretide) in asthma self - management. Eur Respir J 2002; 20 (suppl. 38): 388.
- Kips J.C, O’Connor B.J, Inman M.D et al. A long term study of the antiinflammatory effect of low - dose budesonide plus formoterol versus high dose budesonide in asthma. Am J Respir Crit Care Med 2000; 161 (3), pt 1: 996–1001.
- Konermann M, Luck G, Rawert B, Pirsig W. Effect of the long - acting b2-agonist inhalant formoterol on quality of sleep of patients with bronchial asthma. Pneumologie 2000; 54 (3): 104–9.
- Kotani Y, Nishimura Y, Maeda H, Yokoyama M. Beta2-adrenergic receptor polymorphisms affect airways responsiveness to salbutamol in asthmatic. J Asthma 1999; 36 (7): 583–90.
- Liggett S.B. Polymorphism of the b2-adrenergic receptor and asthma. Am J Respir Crit Care Med 1997; 156 (4), pt 2: 156–62.
- Lima J.J, Thomasson D.B, Mohamed M.H et al. Impact of genetic polymorphism of the b2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol 1999; 65 (5): 519–25.
- Lipworth B.J, Hall I.P, Aziz I et al. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short - and long - acting beta2-agonist therapy. Clin Sci 1999; 96 (3): 253–9.
- Lipworth B.J, Hall I.P, Aziz I et al. Beta2-adrenoceptor polymorphism and bronchoprotective sensitivity with regular short - and long - acting beta2-agonist therapy. Clin Sci 1999; 96 (3): 253–9.
- Malimard M, Bourcereau J, Le Gros V et al. Comparison between formoterol 12 microg b.i.d. and on - demand salbutamol in moderate persistent asthma. Respir Med 2001; 95 (1): 64–70.
- Maneechotesuwan K, Essilfie-Quaye S, Meah S et al. Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 2005; 128 (4): 1936–42.
- Moore R.H, Khan A, Dickey B.F. Long - acting inhaled b2-agonists in asthma therapy. Chest 1998; 113 (4): 1095–105.
- Nelson H.S, Weiss S, Bleeker E.R et al. The Salmeterol Multicenter Asthma Research Trial. A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129 (1): 15–26.
- Nightingale J.A, Rogers D.F, Barnes P.J. Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Respir Crit Care Med 1999; 159 (6): 1786–90.
- Overbeek S.E, Mulder P.G, Baelemans S.M et al. Formoterol added to low - dose budesonide has no additional anti - inflammatory effect in asthmatic patients. Chest 2005; 128 (3): 1121–7.
- Palmqvist M, Persson G, Lazer L et al. Inhaled dry - powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10 (11): 2484–9.
- Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160 (1): 244–9.
- Pauwels R.A, Lofdahl C.G, Postma D.S et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and corticosteroids establishing therapy (FACET) international study group. N Engl J Med 1997; 337 (20): 1405–11.
- Pauwels R.A, Sears M.R, Campbell M et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787–94.
- Qing F, Rahman S.U, Rhodes C.G et al. b - Adrenergic receptors in vivo and lung function in drug - free asthmatic subjects. Am J Respir Crit Care Med 1997; 155: A855.
- Rider N.L, Craig T.J. A safety review of long acting b2-agonists in patients with asthma. J Am Osteopath Assoc 2006; 106 (9): 562–7.
- Rosenborg J, Larsson P, Tenger K, Hallstrom G. Mass balance and metabolism of [3H] Formoterol in healthy men after combined i.v. and oral administration - mimicking inhalation. Drug Metab Dispos 1999; 27 (10): 1104–16.
- Rubinfeld A.R, Scicchitano R, Hunt B et al.Fprmoterol Turbuhaler as a reliever medication in patients with acute asthma. Eur Respir J 2006; 26 (4): 735–41.
- Stahl E, Postma D.S, Svensson K et al. Formoterol used as needed improves health - related quality of life in asthmatic patients uncontrolled with inhaled corticosteroids. Respir Med 2003; 97 (9): 1061–6.
- Tatersfield A.E, Lofdahl C.G, Postma D.S et al. Comparison of formoterol and terbutaline for as - needed treatment of asthma: a randomized trial. Lancet 2001; 357 (9252): 257–61.
- Ueki J, Rhodes C.G, Hughes J.M.B et al. In vivo quantification of pulmonary b - adrenoceptor density in humans with (S)-11C - CGP12177 and PET. J Appl Physiol 1993; 75: 559–65.
- van Noord J.A, Smeets J.J, Raaijmakers J.A et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996; 9 (8): 1684–8.
- Wallin A, Sandstorm T, Soderberg M et al. The effect of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indicies in mild asthma. Am J Respir Crit Care Med 1999; 159 (1): 79–86.
- Wolfe J, La Force C, Friedman B et al. Formoterol, 24 mg bid and serious asthma exacerbations. Similar rates compared with formoterol, 12 mg bid, with and without extra doses taken on demand, and placebo. Chest 2006; 129 (1): 27–38.
- Woodcock A, Acerbi D, Poli G. Modulite® technology: pharmacodynamic and pharmacokinetic implications. Respir Med 2002; 96 (suppl. D): 9–15.
Дополнительные файлы
